SLS (SELLAS Life Sciences Group) YoY EPS Growth: 28.57% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLS SELLAS Life Sciences Group Inc SLS
25 GF Score
Price $11.21
View Full Analysis

What is SELLAS Life Sciences Group YoY EPS Growth?

SELLAS Life Sciences Group SLS +12.20% 25 YoY EPS Growth is 28.57% as of Mar. 2026. GuruFocus rates SLS with a GF Score™ of 25/100.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. SELLAS Life Sciences Group's YoY EPS Growth for the quarter that ended in Mar. 2026 was 28.57%.

SELLAS Life Sciences Group's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $-0.05.

SELLAS Life Sciences Group YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for SELLAS Life Sciences Group's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SELLAS Life Sciences Group YoY EPS Growth Chart

SELLAS Life Sciences Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.49 -58.96 37.09 62.69 50.00

SELLAS Life Sciences Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.67 46.15 40.00 37.50 28.57
SLS
25GF Score
SELLAS Life Sciences Group Inc SLS
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SELLAS Life Sciences Group YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

SELLAS Life Sciences Group's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-0.25--0.5)/ | -0.5 |
=50.00 %

SELLAS Life Sciences Group's YoY EPS Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EPS Growth (Q: Mar. 2026 )
=(Earnings per Share (Diluted) (Q: Mar. 2026 )-Earnings per Share (Diluted) (Q: Mar. 2025 )) / | Earnings per Share (Diluted) (Q: Mar. 2025 )) |
=(-0.05--0.07)/ | -0.07 |
=28.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 28.57% mean?
SELLAS Life Sciences Group (SLS) has a YoY EPS Growth of 28.57% as of Mar. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for SELLAS Life Sciences Group and its competitors.
Is SELLAS Life Sciences Group's YoY EPS Growth too high?
SELLAS Life Sciences Group's current YoY EPS Growth is 28.57%. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's YoY EPS Growth compare to IOVA and COAG?
SELLAS Life Sciences Group's YoY EPS Growth of 28.57% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for SELLAS Life Sciences Group and its competitors. SELLAS Life Sciences Group's current YoY EPS Growth is 28.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current YoY EPS Growth of 28.57%. The current YoY EPS Growth is 28.57%. SELLAS Life Sciences Group's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current YoY EPS Growth is 28.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SELLAS Life Sciences Group Business Description

Other Exchanges RXK3:Germany
Address 7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score

Get the complete analysis for SLS

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.21
Price